1. Home
  2. MCHX vs DBVT Comparison

MCHX vs DBVT Comparison

Compare MCHX & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCHX
  • DBVT
  • Stock Information
  • Founded
  • MCHX 2003
  • DBVT 2002
  • Country
  • MCHX United States
  • DBVT France
  • Employees
  • MCHX N/A
  • DBVT N/A
  • Industry
  • MCHX Business Services
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MCHX Consumer Discretionary
  • DBVT Health Care
  • Exchange
  • MCHX Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • MCHX 79.9M
  • DBVT 67.8M
  • IPO Year
  • MCHX 2004
  • DBVT N/A
  • Fundamental
  • Price
  • MCHX $1.70
  • DBVT $0.59
  • Analyst Decision
  • MCHX
  • DBVT Strong Buy
  • Analyst Count
  • MCHX 0
  • DBVT 2
  • Target Price
  • MCHX N/A
  • DBVT $6.00
  • AVG Volume (30 Days)
  • MCHX 33.5K
  • DBVT 2.0M
  • Earning Date
  • MCHX 10-31-2024
  • DBVT 11-06-2024
  • Dividend Yield
  • MCHX N/A
  • DBVT N/A
  • EPS Growth
  • MCHX N/A
  • DBVT N/A
  • EPS
  • MCHX N/A
  • DBVT N/A
  • Revenue
  • MCHX $48,594,000.00
  • DBVT $12,515,000.00
  • Revenue This Year
  • MCHX N/A
  • DBVT N/A
  • Revenue Next Year
  • MCHX $4.20
  • DBVT $2,860.00
  • P/E Ratio
  • MCHX N/A
  • DBVT N/A
  • Revenue Growth
  • MCHX N/A
  • DBVT 125.54
  • 52 Week Low
  • MCHX $1.11
  • DBVT $0.50
  • 52 Week High
  • MCHX $2.15
  • DBVT $2.14
  • Technical
  • Relative Strength Index (RSI)
  • MCHX 45.01
  • DBVT 34.55
  • Support Level
  • MCHX $1.67
  • DBVT $0.56
  • Resistance Level
  • MCHX $1.90
  • DBVT $0.81
  • Average True Range (ATR)
  • MCHX 0.13
  • DBVT 0.05
  • MACD
  • MCHX -0.00
  • DBVT -0.02
  • Stochastic Oscillator
  • MCHX 33.33
  • DBVT 10.42

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Share on Social Networks: